Gilead Sciences, Inc.
$133.48
$0.79(0.60%)
Gilead Sciences, Inc.
GILD
$133.48
$0.79(0.60%)
Gilead Sciences, Inc.
GILD
NASDAQ
$133.48
$0.79(0.60%)
Chart
Upcoming Earnings
Next report date
May 7, 2026
Report period
Q2 2026
EPS Estimate
$1.89
Revenue Estimate
$6.91B
Key stats
52-Week Range$133.48
$95.30
$157.29
Market capitalization
$165.68BDividend yield (indicated)
2.42%Price to earnings Ratio (TTM)
19.21Basic EPS (TTM)
$6.85Net income (TTM)
$8.51BRevenue (TTM)
$29.44BAvg. volume
6.39MBeta (1Y)
0.33Employees
17.60KMarket capitalization
$165.68BDividend yield (indicated)
2.42%Price to earnings Ratio (TTM)
19.21Basic EPS (TTM)
$6.85Net income (TTM)
$8.51BRevenue (TTM)
$29.44BAvg. volume
6.39MBeta (1Y)
0.33Employees
17.60KScreener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Gilead Sciences, Inc.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
Website
www.gilead.comHeadquarters
333 Lakeside Drive, Foster City, CA, 94404
IPO Date
1992-01-22
Identifiers
ISIN
US3755581036Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet...
Related Stocks
$113.16
1D:
0.0%
1Y:
36.6%
US58933Y1055Healthcare
Mkt Cap
$279.49B
P/E Ratio TTM
31.0
Revenue TTM
$65.01B
Beta
0.28
Earnings TTM
$18.25B
Dividend Yield TTM
2.96%
$44.89
1D:
1.1%
1Y:
-35.1%
US6701002056Healthcare
Mkt Cap
$199.49B
P/E Ratio TTM
12.1
Revenue TTM
$309.06B
Beta
0.27
Earnings TTM
$102.43B
Dividend Yield TTM
4.21%
Dividend Overview
Dividend yield (indicated)
2.42%
Dividend per share
$3.19annual
Payout ratio (Earnings)
47.0%
Payout ratio (FCF)
41.9%
Dividend growth streak
0
Dividend CAGR (3Y)
-35.1%
Dividend CAGR (5Y)
-22.0%
Dividend CAGR (10Y)
-7.8%
Dividend yield (indicated)
2.42%
Dividend per share
$3.19annual
Payout ratio (Earnings)
47.0%
Payout ratio (FCF)
41.9%
Dividend growth streak
0
Dividend CAGR (3Y)
-35.1%
Dividend CAGR (5Y)
-22.0%
Dividend CAGR (10Y)
-7.8%
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate